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Introduction
Tuberculosis (TB) is a serious disease afflicting humans; it results in millions of deaths and new cases each year. 1, 2 The only available vaccine against TB is attenuated Mycobacterium bovis bacille Calmette-Guérin (BCG). However, the protective efficacy of BCG against TBdespecially adult TBdremains controversial. 3 A more efficacious and satisfactory vaccine to fight against TB is therefore urgently required.
Studies have been performed in past decades to develop novel TB vaccines such as rBCG vaccines, 4, 5 live attenuated vaccines, 6 subunit vaccines, 7 and DNA vaccines. 8 However, no vaccine has exceeded BCG in conferring protection from Mycobacterium tuberculosis infection in mankind. Recombinant BCG (rBCG) is a promising approach to promote the immune efficacy of the BCG vaccine by importing exogenous genes that encode immunodominant antigens of M. tuberculosis or immunoregulatory cytokines. By rBCG technology, the proteins secreted by BCG and recombinant proteins introduced to BCG can simultaneously stimulate the body to generate stronger immune responses to M. tuberculosis infection. The rBCG vaccine shares many advantages of the BCG vaccine such as safety and low adverse effects. It can be vaccinated in the form of a viable organism and it is capable of longterm selfproduction in the body, 9 allowing it to stimulate sustained immune responses against M. tuberculosis infection. In recent years, studies for developing a better TB vaccine than BCG have therefore been focused on the rBCG vaccine.
Early secretory antigen target 6 (ESAT-6) is only present in the virulent M. tuberculosis, but is lacking in BCG. 10 It can induce strong cell-mediated immunity. 11, 12 It has been considered a protective antigen for developing TB vaccines. 13 Ag85A is a major fraction of the Ag85 complex (which comprises Ag85A, Ag85B, and Ag85C). These AG85 components are proteins that are secreted in M. tuberculosis culture filtrate. 14, 15 Ag85A is the most essential component of M. tuberculosis for immunostimulation and has been used in numerous vaccine preparations that can induce outstanding protective efficacy. 16 Ag85A, moreover, is closely correlated with the longterm survival of M. tuberculosis within macrophages. 17 M. tuberculosis within macrophages may be effectively eliminated when the immune responses against Ag85A are induced. For these reasons, we previously chose Ag85A and ESAT-6 to construct rBCG (rBCG-AE) for stimulating more potent immune responses against M. tuberculosis infection; the study showed that in BALB/c mice the vaccine was able to induce a higher titer of antibody, elicit a greater CD4 þ T and CD8 þ T proliferation rate of splenocytes, and elevate the level of interferon-gamma (IFN-g) production, compared to the parental BCG. The study suggested that the immunogenicity of the parental BCG was significantly improved. 18 Eliciting prominent immunogenicity is insufficient for a satisfactory TB vaccine. Our ultimate goal is to develop a vaccine that effectively prevents M. tuberculosis infection. In the current study, we therefore further evaluated the protective efficacy conferred by rBCG-AE vaccine against M. tuberculosis H37Rv infection in BALB/c mice.
Materials and methods

Bacterial strains and media
M. bovis BCG-China was obtained from the Chengdu Biological Products Institute (Chengdu, China). M. tuberculosis H37Rv (strain ATCC 93009) was originally conserved in the Animal Bio-Safety Level 3 (ABSL-3) facility of Wuhan University (Wuhan, China). The rBCG vaccines were previously constructed and included rBCG-AE (which expresses the Ag85A-ESAT-6 fusion protein), rBCG-A (which only expresses the Ag85A protein of M. tuberculosis), rBCG-E (which only expresses the ESAT-6 protein of M. tuberculosis) and rBCG-361(BCG strains transformed with pMV361 plasmids). 18 They were cultivated in Sauton medium (i.e., 0.5 g MgSO 4 , 0.5 g K 2 HPO 4 , 2 g citric acid, 8 g sodium glutamate, 60 mL glycerol, 0.01 g ZnSO 4 , and 0.05 g ferrumammonium citrate in 1000 mL at a pH7 ranging approximately from 4 to 7.5).
Animals
Pathogen-free BALB/c female mice were obtained from the Laboratory Animal Research Center, Second Military Medical University (Shanghai, China). The mice were 4e5 weeks old at the time of vaccination. All of the animals were housed under controlled conditions at the ABSL-3 facility of Wuhan University (Wuhan, China). The animals were managed by using welfare animal practices.
Animal immunization
Fifty-four female BALB/c mice were randomly divided into 6 groups: (1) phosphate-buffered salineeTween-80 (PBST) group; (2) BCG group; (3) rBCG-361 group; (4) rBCG-E group; (5) rBCG-A group; and (6) rBCG-AE group. The mice were immunized subcutaneously with either BCG or rBCG vaccine at a dose of 5 Â 10 6 colony-forming units (CFUs), which was suspended in PBST (0.01M PBS containing 0.05% Tween-80, V/V) (Sigma, St. Louis, MO) in a volume of 0.1 mL. The control animals (i.e., PBST group) were sham-immunized with PBST only. All animals were immunized once. The protective experiment was performed at 10 weeks after vaccination.
Challenge infection
Ten weeks after immunization, the mice (nine mice per group) were infected intravenously (i.v.) via the lateral tail vein with 1 Â 10 6 CFUs of virulent M. tuberculosis H37Rv. Three mice in each group were sacrificed at 3 weeks, 6 weeks, and 9 weeks after the challenge to evaluate the respective protective efficacy. The mice were weighed before being killed. The spleen and lung tissues from immunized mice were removed aseptically. One-half of the spleen (v/v) and the right lung lobe from each mouse were used for culture to determine the M. tuberculosis loads in the tissues. The left lung and the rest half spleen tissues were used for acid-fast staining, hematoxylin and eosin (H&E) staining, and evaluated by light microscopy. 19 The protective experiment was performed once. All animal protocols were approved by the institutional animal experimentation committee.
Colony-forming unit detection
The bacterial loads in the lung and spleen tissues were performed 3 weeks, 6 weeks, and 9 weeks after infection with M. tuberculosis H37Rv. The organs were removed aseptically and washed with sterile PBS. The colonyforming unit (CFU) was performed in serial dilutions of the homogenate and plated onto Middlebrook 7H11þOADC agar. The CFU could be determined 4 weeks after incubation at 37 C.
Histopathological analysis
The lung tissues from the mice challenged with M. tuberculosis H37Rv were fixed in 10% formalin for 72 hours, dehydrated by a graded ethanol series, embedded in paraffin for 5-mm sections. The sections were stained with H&E. The lung tissue sections were evaluated by acid-fast staining to determine M. tuberculosis numbers. Pathologists from the ABSL-3 facility (Wuhan, China) evaluated the results by using the Leica system (Leica, Heidelberg, Germany). According to observed histopathological changes (e.g., peribronchiolitis, perivasculitis, alveolitis, and granuloma formation), the lung pathology was scored as 0, 1, 2, 3, 4, or 5 for absent, minimal, slight, moderate, marked, or strong changes, respectively; the maximum sum was 20.
Analysis of lung acid-fast stains
The M. tuberculosis number in the lung tissues was determined through acid-fast staining. A pathologist who had no prior knowledge of the experimental groups counted the M. tuberculosis numbers in each tissue section under a light microscope. The pathologist evaluated the sample at least twice to verify the reproducibility of the observations. The M. tuberculosis number in a random area of 0.25 cm 2 in each section was counted. Five tissue sections were counted from each detected sample, the results are presented as the mean AE the standard error.
Immunohistochemistry staining for detection of the IFN-g and iNOS expression in the lung tissues
To investigate the expression of IFNeg and inducible nitric oxide synthase (iNOS) in lung tissues from infected mice with M. tuberculosis, the lung tissues from challenged animals were fixed by 10% formalin for 72 hours and were then embedded in paraffin for 5-mm sections. The lung sections were deparaffinized with xylene and gradually dehydrated in ethyl alcohol. The sections were then immersed in a citric acid buffer (pH 6.0) in a microwave oven for 10 minutes to perform antigen retrieval. Endogenous peroxidase activity and nonspecific binding were blocked with 3% hydrogen peroxide for 15 minutes and 10% normal goat serum for 15 minutes, respectively. Rabbit anti-mouse IFN-g and iNOS IgG (eBioscience, San Diego, CA) were added at a dilution of 1:200 for 1 hour at 37 C by using 1:200 diluted normal rabbit serum under the same conditions as the negative control. Slides were then incubated with biotinylated anti-rabbit immunoglobulin in a humidified chamber for 20 minutes. The reaction was visualized by using the substrate diaminobenzidine (DAB). The sections were afterward counterstained with hematoxylin. Under a light microscope, the cytoplasm of IFN-g and iNOS positive cells was stained brown-yellow. The results were evaluated by the percentage of positive cells. Under highpower microscopy (magnification of Â400), the number of positive cells and the total number of cells in the lung tissues were counted from 10 randomly selected fields in each section. Five tissue sections were also counted from each detected sample. All counting was manually performed by an investigator who was blinded to the treatment groups. The percentages are represented as the mean AE standard errors.
Statistical analysis
The measurement data are represented as the mean AE standard error. The variance comparison was made using the Student F test. The differences were considered statistically significant when the probability values were less than 0.05. The statistical tests were run on SPSS software (Version.13.0, IBM Corporation, NY, USA).
Results
Determination of bacterial loads
The lung and spleen tissues from the mice of groups were obtained 3 weeks, 6 weeks, and 9 weeks after infection with M. tuberculosis H37Rv to culture for bacterial colonization. Mice immunized with rBCG vaccines had a reduced number of CFUs in the lung (Fig. 1A ) and spleen tissues (Fig. 1B) , compared to the control group (i.e., PBST group). From the 3rd to the 9th week after the challenge infection, the bacterial count in the tissues (including the spleen and lung tissues) of the mice immunized with BCG were significantly lower than the count in the tissues of the rBCG-AE, rBCG-A, and rBCG-E groups. The mice in the BCG group also gained the most weight of all the groups (Fig. 1C) .
Pathological examinations
To evaluate pathological changes, lung tissues from the mice were fixed, sectioned and stained with H&E. Three weeks after the challenge, the lungs of the mice of each group showed many small tubercles, a small number of great tubercles, and alveolitis. The pathological changes were not different among the groups. Six weeks after the infection, extensive serious pathological changes were present with strong peribronchiolitis, perivasculitis and alveolitis, and several tubercles in the lungs of mice immunized with rBCG-AE, rBCG-361, rBCG-A, rBCG-E, or PBST. The pathological damage was comparatively much less in the lungs of the mice vaccinated with BCG from the 6th to the 9th week after the challenge infection. Both the extent and severity of lung pathology gradually attenuated in the group immunized with BCG, and there was only slight damage in alveolar tissue at the 9th week after the challenge (Fig. 2D ), compared to normal lung tissue ( Fig. 2A) . However, the lung sections from the PBST group showed severe interstitial pneumonia and intense inflammation throughout the lung (Fig. 2B ). In the rBCG-AE groups, there was still a large number of lymphocytes and inflammatory exudates in the lung tissue at the 9th week after the challenge infection (Fig. 2C) . At the same time, the lung pathology score in the BCG group was significantly lower than the score in the rBCG-AE group (Fig. 2E) .
Acid-fast staining
The results of acid-fast staining clearly illustrated that the M. tuberculosis numbers in the lung and spleen tissues from the group immunized with BCG ( Fig. 3D) were lower than their numbers in the PBST group (Fig. 3B) or rBCG-AE group ( Fig. 3C and E) . This is consistent with the results of bacterial load experiments. There was no M. tuberculosis in the normal lung tissue (Fig. 3A) .
Detection of immunohistochemistry staining
The lung tissues were stained by immunohistochemistry to detect the amount of IFN-g and iNOS expression 3 weeks, 6 weeks, and 9 weeks after infection with Mycobacterium tuberculosis H37Rv. Results showed that from the 3rd to the 9th week after the challenge, the percentage of cells positive for IFN-g ( Fig. 1) and iNOS ( Fig. 2) were obviously higher in the lung tissues of animals vaccinated with BCG and rBCG vaccines than in the PBST group. There was no statistical difference among the vaccine groups (including the rBCG vaccine groups and BCG group).
Discussion
Previous research revealed that the rBCG-AE strain is able to express the Ag85A-ESAT-6 fusion protein, whereas the BCG strain could not secrete this protein. This suggests that the rBCG-AE strain had obtained more of the stimulation antigen. We then evaluated its immunogenicity and illustrated that the rBCG-AE strain could induce a higher titer of antibody and elicit more long-lasting and stronger T helper 1 (Th1)-type cellular immune responses than the parental BCG strain. 18 In this study, To investigate the ability of the rBCG-AE strain to defend against M. tuberculosis infection, we further evaluated its protective efficacy in BALB/c mice. We chose BALB/c mice because they are promising small animal models that many related studies have used for the preliminary evaluation of new TB vaccine candidates. 20, 21 The protective efficacy will be further evaluated in large animal models such as the monkey when the immunization efficacy is confirmed as better than the efficacy now provided by the parental BCG in BALB/c mice models.
Compared to BCG strain, the rBCG-AE strain is able to elicit stronger antibody responses, activate greater splenocyte proliferation, and produce higher levels of IFNeg. 18 To our surprise, the protective experiments in this study showed that none of the rBCG vaccines exceeded the The results of the net weight gain or loss shows that the weight loss is even greater in the rBCG-AE group than in the BCG group during the challenge infection, indicating that the virulence of rBCG-AE may be increased.
parental BCG vaccine in the protection from M. tuberculosis H37Rv infection. The bacterial counts in the lung and spleen tissues from the mice immunized with rBCG-A, rBCG-E, or rBCG-AE were significantly lower than in animals injected with PBST, but obviously higher than in animals vaccinated with BCG. This suggests that the parental BCG has a greater ability to eliminate the M. tuberculosis in the tissues (Fig. 1) . This finding was further confirmed by the results of the acid-fast staining, which illustrated that the M. tuberculosis numbers in the spleen and lung tissues from the group immunized with BCG were the lowest among groups (Fig. 3) . The pathological examination also showed that, after M. tuberculosis H37Rv infection, the pathological damage in the lung tissue was much less in the BCG group than in the other groups (Fig. 2) . The Th1 cytokine IFN-g is essential to immunity by preventing damage from intracellular pathogens. It is able to activate macrophages that inhibit or eliminate M. tuberculosis in the lung tissue. 22 The effector molecule nitric oxide (NO), which is produced by activity of phagocytes in the lung tissue, is enzymatically generated in immune and inflammatory situations by iNOS. 23 The molecule iNOS plays a crucial role in host defense against mycobacterial infections; it is activated by IFN-g. 24 In our study, we therefore investigated the effect of immunization on the induction of IFN-g by measuring iNOS expression in the lung tissues. Studies have also reported that macrophages and immune effector cells secreting IFN-g in the lung (but not in spleen) is able to fight against M. tuberculosis infection. 25 Nitric oxide is mainly produced by activated macrophages in the lung tissue during pulmonary tuberculosis. 26 Hence, in our study their expression only in the lung tissues were measured by immunohistochemistry. The results showed that (IFN)-g and iNOS expression in the lung tissues from the mice vaccinated with rBCG were similar to their expression in mice immunized with BCG (Fig. 4) . This indicated that the rBCG vaccines were unable to improve the expression of the molecules in the lung tissues, compared to the BCG vaccine.
The protective efficacy of rBCG-AE should logically be higher than the parental BCG when the immunodominant antigens ESAT-6 and Ag85A are added into BCG. The protective efficacy of rBCG-AE unfortunately was not enhanced and was even lower than the parental BCG. Possible reasons that rBCG-AE vaccine failed to improve the protective efficacy of BCG may be the following. One, rBCG-AE is able to induce increased expression of IFN-g in splenocytes 8 but unable to stimulate the production of IFN-g and iNOS in the lung tissues (which the results of immunohistochemistry staining supported). This may be the reason the rBCG-AE vaccine failed to elicit improved protective efficacy. Two, ESAT-6 is a type of virulent protein of M. tuberculosis 27 and can inhibit T cell responses and IFN-g production. 28, 29 Thus, the virulence of rBCG-AE may increase and weight changes may reflect the increased virulence since weight loss was greater in the mice in the rBCG-AE group than in the BCG group (Fig. 1C) . The increased virulence was not conducive to immune activation during immunostimulation. Three, recent studies have reported that the protective efficacy of BCG could be significantly promoted through rBCG technology, and the parental BCG used in other experiments was the BCG-Tokyo strain, 30 the BCG-Danish strain, 31 or the BCG-Pasteur strain, 32 whereas we chose the BCG-China strain as the parental BCG in our study. Researchers have found that different BCG strains induce different immunity and have different unknown immune mechanisms. 33 Therefore, the choice of parental BCG has a great effect on the immune efficacy of the rBCG vaccine. Four, the methods of vaccination and the administration dose are also critical in stimulating satisfactory immune protection. Figure 4 . Expression of cytokines of interferon-gamma and inducible nitric oxide synthase in the lung tissues from the mice infected with M. tuberculosis H37Rv. At 3 weeks, 6 weeks, and 9 weeks after the challenge infection, the lung tissues from each group of mice were obtained and embedded in paraffin for 5-mm sections. The tissue sections were stained by immunohistochemistry to detect the expression of interferon-gamma (IFN-g) and inducible nitric oxide synthase (iNOS) expression. (BeD and FeH) the expression of IFNeg and iNOS, respectively, in the lung tissues from the PBST, rBCG-AE, and BCG groups at 9 weeks after infecting the mice with M. tuberculosis H37Rv. (A and E) the negative controls in which PBS was added, instead of IFNeg or iNOS antibody. The percentage of (i) positive IFNeg cells and (ii) positive iNOS cells in the lung tissues of mice vaccinated with BCG and rBCG vaccine were obviously higher than the their percentage in the PBST group. There is no statistical difference among vaccine groups (including the rBCGs and BCG groups). *p < 0.01, versus other groups. The arrows (➔) show the cells positive for IFNeg and iNOS.
Much work may be needed to improve the protective efficacy of rBCG vaccines such as (1) choosing other parental BCG strains such as the BCG-Pasteur strain to construct an rBCG vaccine; (2) utilizing better administration methods (e.g., intranasal vaccination) to induce satisfactory immunization effects; (3) screening the optimal dose for vaccination to induce better immune responses; (4) changing immunization strategies to stimulate more potent immunity and thereby promote protective efficacy; and (5) investigating why rBCG-AE is able to significantly promote immunogenicity but not improve the protective efficacy in comparison to the parental BCG. In conclusion, our study suggested that an rBCG strain expressing an Ag85A-ESAT-6 fusion protein can not promote protective efficacy against M. tuberculosis H37Rv infection, compared to the parental BCG.
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